专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2005119931A Laminated foamed glass and its producing method 有权
标题翻译：层压泡沫玻璃及其生产方法
公开(公告)号：JP2005119931A
公开(公告)日：2005-05-12
申请号：JP2003359416
申请日：2003-10-20
申请人： Takayuki Maruyama , Kazuyoshi Mizuno , 隆之丸山 , 和喜水野
发明人： MARUYAMA TAKAYUKI , MIZUNO KAZUYOSHI
IPC分类号： B32B17/06 , C03B23/203
CPC分类号： B32B17/06
摘要： PROBLEM TO BE SOLVED: To provide a laminated foamed glass which is hardly scratched, has improved chemical resistance and wear resistance, and is hardly attached with stains, from which stains can be easily wiped off even if the stains attach, and which has markedly improved durability, is super lightweight and excellent in heat shielding property and strength, and can sustain the effect of luminous or fluorescent property in a brilliant state for a remarkably long period in comparison with a conventional article, obtained by coating the surface of glass with a luminous coating material or a fluorescent coating material; and to provide a method for producing the same.
SOLUTION: The laminated foamed glass 1 is obtained by melt-bonding a sheet-like glass layer 11, a layer 12 of a decorative agent containing one or more kinds selected from luminous substances, fluorescent substances and colorants, and a foamed glass material layer 13 in this order, and the method for producing the laminated foamed glass 1 is also provided.
COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：为了提供几乎不被划伤的层压泡沫玻璃，具有改善的耐化学性和耐磨性，并且几乎不附着污渍，即使污渍附着，污渍也可以容易地被擦去，并且哪些具有显着提高的耐久性，超轻量化，隔热性和强度优异，并且与通过涂布玻璃的表面获得的常规制品相比，可以显着地延长亮度或荧光性能在明亮状态下的显着长时间的效果具有发光的涂层材料或荧光涂层材料; 并提供其制造方法。解决方案：层压发泡玻璃1通过熔融粘合片状玻璃层11，含有选自发光物质，荧光物质和着色剂中的一种或多种的装饰剂层12和发泡玻璃材料层13，以及层压发泡玻璃1的制造方法。版权所有（C）2005，JPO＆NCIPI

2. 发明授权

US08507545B2 Cytotoxic T cell activator comprising EP4 agonist 失效
标题翻译：包含EP4激动剂的细胞毒性T细胞活化剂
公开(公告)号：US08507545B2
公开(公告)日：2013-08-13
申请号：US12599194
申请日：2008-05-07
申请人： Masahiro Takigawa , Naohiro Seo , Kenji Kabashima , Takayuki Maruyama , Toshiya Kanaji
发明人： Masahiro Takigawa , Naohiro Seo , Kenji Kabashima , Takayuki Maruyama , Toshiya Kanaji
IPC分类号： A61K31/40 , A61K31/10
CPC分类号： A61K31/5575 , A61K39/0011 , A61K39/12 , A61K39/245 , A61K45/06 , A61K2039/55588 , A61K2039/57 , C12N2710/16634 , A61K2300/00
摘要： Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease.An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.
摘要翻译：公开了具有低分子量的物质，可以以更简单的方式施用，并且具有抗癌和/或微生物介导的感染性疾病的免疫增强活性。 EP4激动剂通过激活细胞毒性T细胞表现出免疫增强活性，因此可用于预防和/或治疗癌症或微生物介导的感染疾病。

3. 发明申请

US20120202773A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT 审中-公开
标题翻译：用于治疗与包含EP4激动剂作为主动成分的骨质疏松相关的疾病的药物组合物
公开(公告)号：US20120202773A1
公开(公告)日：2012-08-09
申请号：US13453434
申请日：2012-04-23
申请人： Toru Maruyama , Kaoru Kobayashi , Tohru Kambe , Takayuki Maruyama , Hideyuki Yoshida , Akio Nishiura , Nobutaka Abe
发明人： Toru Maruyama , Kaoru Kobayashi , Tohru Kambe , Takayuki Maruyama , Hideyuki Yoshida , Akio Nishiura , Nobutaka Abe
IPC分类号： A61K31/4015 , C08B37/16 , A61K31/724 , C07D409/06 , C07D405/10 , C07D405/06 , C07D417/12 , C07D413/12 , C07D417/14 , C07D263/24 , C07D403/12 , C07D409/12 , C07D409/14 , C07D401/12 , A61P19/08 , C07D413/14 , C07D207/26 , B82Y99/00 , B82Y5/00
CPC分类号： C07C405/0033 , A61K9/0019 , A61K9/1647 , A61K9/19 , A61K9/2054 , A61K31/4015 , A61K31/41 , A61K31/5575 , A61K31/559
摘要： A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).
摘要翻译：用于预防和/或治疗与包含EP4激动剂作为活性成分的骨量减少相关的疾病的局部施用的药物组合物。包含具有前列腺素骨架的化合物作为代表的EP4激动剂具有促进骨形成的作用，因此可用于预防和/或治疗与骨质量减少有关的疾病（骨疾病如原发性骨质疏松症，继发性骨质疏松症骨质疏松症，癌症的骨转移，高钙血症，佩吉特氏病，骨丢失和骨坏死，术后成骨，骨移植的替代疗法）。

4. 发明授权

US08143661B2 Memory cell system with charge trap 有权
标题翻译：带电荷陷阱的记忆体系统
公开(公告)号：US08143661B2
公开(公告)日：2012-03-27
申请号：US11539984
申请日：2006-10-10
申请人： Shenqing Fang , Rinji Sugino , Jayendra Bhakta , Takashi Orimoto , Hiroyuki Nansei , Yukio Hayakawa , Takayuki Maruyama , Hidehiko Shiraiwa , Kuo-Tung Chang , Lei Xue , Meng Ding , Amol Ramesh Joshi , YouSeok Suh , Harpreet Sachar
发明人： Shenqing Fang , Rinji Sugino , Jayendra Bhakta , Takashi Orimoto , Hiroyuki Nansei , Yukio Hayakawa , Takayuki Maruyama , Hidehiko Shiraiwa , Kuo-Tung Chang , Lei Xue , Meng Ding , Amol Ramesh Joshi , YouSeok Suh , Harpreet Sachar
IPC分类号： H01L29/792
CPC分类号： H01L29/792 , H01L21/28273 , H01L27/115 , H01L27/11568
摘要： A memory cell system is provided including a first insulator layer over a semiconductor substrate, a charge trap layer over the first insulator layer, and slot where the charge trap layer includes a second insulator layer having the characteristic of being grown.
摘要翻译：提供一种存储单元系统，包括半导体衬底上的第一绝缘体层，第一绝缘体层上的电荷陷阱层和电荷陷阱层包括具有生长特性的第二绝缘体层的槽。

5. 发明申请

US20090302326A1 SILICON CARBIDE SINGLE CRYSTAL WAFER AND PRODUCING METHOD THEREOF 有权
标题翻译：硅碳化硅单晶及其生产方法
公开(公告)号：US20090302326A1
公开(公告)日：2009-12-10
申请号：US11912207
申请日：2006-04-19
申请人： Takayuki Maruyama
发明人： Takayuki Maruyama
IPC分类号： H01L29/24 , H01L21/20
CPC分类号： H01L21/02529 , C30B25/00 , C30B25/02 , C30B25/18 , C30B29/36 , H01L21/02378 , H01L21/02433 , H01L21/02609 , H01L21/0262 , H01L29/045 , H01L29/24 , H01L29/78
摘要： A silicon carbide single crystal wafer wherein a substrate is cut out at an OFF angle from a (0001) c plane of an α-type silicon carbide single crystal of less than 2° and in an OFF direction in which a deviation from a (11-20) direction is less than 10°, the number of substantially triangular lamination defects exposed from a surface of a wafer which is epitaxial grown on the substrate is less than 4/cm2 over the entire surface of the wafer. The invention provides a producing method of a silicon carbide single crystal wafer capable of enhancing the utility ratio of the bulk silicon carbide single crystal, the element characteristics and the cleavage, as well as a silicon carbide single crystal wafer obtained by such a producing method.
摘要翻译：一种碳化硅单晶晶片，其中从与α（α）的α型碳化硅单晶的（0001）c面成OFF角切割基板，在偏离方向偏离（11 -20）方向小于10°时，从在晶片外延生长的晶片的表面露出的基本上三角形层叠缺陷的数量在晶片的整个表面上小于4 / cm 2。本发明提供了一种能够提高体积碳化硅单晶的利用率，元素特性和切割的碳化硅单晶晶片的制造方法以及通过这种制造方法获得的碳化硅单晶晶片。

6. 发明授权

US07629369B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation 失效
标题翻译： N-苯基芳基磺酰胺化合物，包含该化合物作为活性成分的药物组合物，该化合物的合成中间体及其制备方法
公开(公告)号：US07629369B2
公开(公告)日：2009-12-08
申请号：US11239406
申请日：2005-09-30
申请人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
发明人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
IPC分类号： C07D285/08 , C07D271/06 , C07D257/04 , A61K31/41
CPC分类号： C07D213/70 , C07D277/36 , C07D307/64 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.
摘要翻译：式（I）的N-苯基芳基磺酰胺化合物（R1是COOH等; R2是氢，甲基等; R3和R4是甲基和甲基的组合等; R5是异丙基等; Ar是噻唑基，吡啶基，5-甲基-2-呋喃基，各自任选被甲基取代; n为0或1），化合物的合成中间体及其制备方法。式（I）化合物结合前列腺素E2受体，特别是EP1亚型受体，并拮抗它。蛋白质结合的影响较小，因此具有令人满意的体内活性。因此，认为可用作止痛剂，解热剂，治疗尿频（尿频）和/或下尿路疾病综合征或抗肿瘤药物的药剂。

7. 发明授权

US07335776B2 Remedies for depression containing EP1 antagonist as the active ingredient 失效
标题翻译：含有EP1拮抗剂作为活性成分的抑郁症的治疗方法
公开(公告)号：US07335776B2
公开(公告)日：2008-02-26
申请号：US10471553
申请日：2002-03-13
申请人： Shigeyuki Nonaka , Takayuki Maruyama
发明人： Shigeyuki Nonaka , Takayuki Maruyama
IPC分类号： C07D277/04 , C07D277/08 , A61K31/425 , A01N43/78
CPC分类号： C07D277/36 , A61K31/341 , A61K31/41 , A61K31/4245 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4439
摘要： A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype.EP1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.
摘要翻译：用于治疗和/或预防抑郁症的药物组合物，其包含前列腺素E 2受体亚型的具有拮抗活性的化合物。 EP 1拮抗剂可用于治疗抑郁症，例如内源性抑郁症，反应性抑郁症，耐候性抑郁症，神经性抑郁状态，脑有机精神障碍的抑郁状态。

8. 发明申请

US20080021021A1 Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist 有权
标题翻译：预防和/或补救含有Ep4激动剂的下尿路疾病
公开(公告)号：US20080021021A1
公开(公告)日：2008-01-24
申请号：US11660043
申请日：2005-08-09
申请人： Hiroki Okada , Takayuki Maruyama
发明人： Hiroki Okada , Takayuki Maruyama
IPC分类号： A61K31/535 , A61K31/4164 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/5375 , A61P13/02 , A61K31/54 , A61K31/426 , A61K31/433 , A61K31/495 , A61K31/505
CPC分类号： A61K9/2054 , A61K31/5575 , A61K31/559 , A61K45/06 , A61K2300/00
摘要： (1) A preventive and/or a remedy for lower urinary tract diseases such as inflammation in the lower urinary tract, cystitis (interstitial cystitis, etc.) and urethritis; (2) an agent for improving bladder compliance and/or bladder capacity; and (3) an agent for protecting bladder mucosa and/or bladder epithelial cells and/or promoting the regeneration thereof; each containing an EP4 agonist. An EP4 agonist is useful in ameliorating symptoms of lower urinary tract diseases such as (1) frequent urination, (2) urgency of urination, (3) pain in the reproductive organs and/or lower urinary tract (for example, bladder pain, urinary tract pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and/or (4) discomfort in the reproductive organs and/or lower urinary tract. Among all, a selective EP4 agonist is useful as a preventive and/or remedy for lower urinary tract diseases having no side effect.
摘要翻译：（1）下泌尿道疾病如下泌尿道炎症，膀胱炎（间质性膀胱炎等）和尿道炎的预防和/或补救措施; （2）改善膀胱依从性和/或膀胱容量的药剂; 和（3）用于保护膀胱粘膜和/或膀胱上皮细胞和/或促进其再生的药剂; 每个含有EP 4激动剂。 EP 4激动剂可用于改善下尿路疾病的症状，例如（1）尿频，（2）排尿紧急，（3）生殖器官和/或下泌尿道疼痛（例如，膀胱疼痛，尿路疼痛，外阴疼痛，阴道疼痛，阴囊疼痛，会阴疼痛，骨盆疼痛等）和/或（4）生殖器官和/或下尿路中的不适。其中，选择性EP 4激动剂可用作不具有副作用的下尿路疾病的预防和/或补救措施。

9. 发明申请

US20060254507A1 Silicon carbide single crystal and production thereof 有权
公开(公告)号：US20060254507A1
公开(公告)日：2006-11-16
申请号：US11435762
申请日：2006-05-18
申请人： Masashi Otsuki , Takayuki Maruyama , Shigeki Endo , Daisuke Kondo , Takuya Monbara
发明人： Masashi Otsuki , Takayuki Maruyama , Shigeki Endo , Daisuke Kondo , Takuya Monbara
IPC分类号： C30B23/00 , C30B25/00 , C30B28/12 , C30B28/14
CPC分类号： C30B23/025 , C30B29/36
摘要： A method of producing a silicon carbide single crystal, having: fixing a seed crystal, including setting a seed crystal on a seed crystal fixing part with interposition of an adhesive; applying a uniform pressure on the entire surface of the seed crystal by contacting a flexible bag which is inflatable and deflatable to the seed crystal by charging a gas into the to flexible bag; hardening the adhesive; and sublimating a silicon carbide powder obtained by calcinating a mixture containing at least a silicon source and a resol xylene resin, having a nitrogen content of 100 mass ppm or less and having a content of each impurity elements of 0.1 mass ppm or less, and re-crystallizing for growing a silicon carbide single crystal.

10. 发明申请

US20060100195A1 Remedies for urinary frequency 审中-公开
标题翻译：尿频治疗
公开(公告)号：US20060100195A1
公开(公告)日：2006-05-11
申请号：US10495979
申请日：2002-11-18
申请人： Takayuki Maruyama , Shigeyuki Nonaka
发明人： Takayuki Maruyama , Shigeyuki Nonaka
IPC分类号： A61K31/554 , A61K31/195 , A61K31/497
CPC分类号： A61K31/19 , A61K31/501 , A61K31/553
摘要： The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).
摘要翻译：本发明涉及用于治疗和/或预防尿频的药剂，其包含对作为前列腺素E 2受体亚型的EP 1受体具有拮抗作用的化合物。具有拮抗EP 1受体的化合物拮抗作用于作为前列腺素PGE 2受体亚型的EP 1受体，并显着地显示出引起尿频的模型中排尿频率的抑制活性。因此，对于尿尿症（由于神经源性膀胱，神经性膀胱，刺激性膀胱，膀胱不稳定，良性前列腺肥大等引起）的治疗和/或预防是有效的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式